Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia
Launched by ASTRAZENECA · Dec 2, 2009
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks. ·
- • Subject must sign informed consent
- Exclusion Criteria:
- • Subjects who are unwilling or unable to provide informed consent.
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riyadh, Central, Saudi Arabia
Dammam, Eastern, Saudi Arabia
Aljouf, North, Saudi Arabia
Jeddah, Western, Saudi Arabia
Makah, Western, Saudi Arabia
Patients applied
Trial Officials
Prof. Mohammed Arafah
Study Chair
King Khalid University Hospital
Dr. Shorook Alherz
Principal Investigator
King Fahad National Guard Hospital
Dr. Khalid Alnemer
Principal Investigator
Security Forces Hospital
Dr. Hossam Alghetany
Principal Investigator
Soliman Fakieh Hospital
Dr. Othman Metwally
Principal Investigator
King Fahad General Hospital
Dr. Akram Alkhadra
Principal Investigator
King Fahad University Hospital
Dr. Faisal Alanizi
Principal Investigator
Ministry of Health, Saudi Arabia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials